Julie R Park

21PUBLICATIONS

173CO-AUTHORS

Molecular targetsInfant and child healthPredictive and prognostic markersHaematological tumoursSolid tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (21)

Sort by Publication Date:

|Jun 18, 2026

The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma.

|Dec 23, 2025

Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.

Wendy B London, Gabriela Villanueva, Derek Shyr

|Oct 27, 2025

Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.

Florette K Hazard, Angus M S Toland, Serena Y Tan

|Sep 17, 2025

RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity.

Shivendra Singh, Jie Fang, Hongjian Jin

|Aug 12, 2025

A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors.

Kenneth B DeSantes, Kimberly A McDowell, Paul M Sondel

|Jun 23, 2025

Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Thomas Cash, Araz Marachelian, Steven G DuBois

Pageof 4

Frequent Collaborators

Wenjun Huang

Navin Pinto

Rebecca Gardner

Arlene Naranjo

John M Maris

Nicholas A Vitanza

Meredith S Irwin

Rochelle Bagatell

Susan L Cohn

Ashley L Wilson

Frequent Collaborators

Wenjun Huang

Navin Pinto

Rebecca Gardner

Arlene Naranjo